Vol. 9: January-December 2022

Published: 2022-01-25

Point of View

How reliable are ICER’s results published in current pharmacoeconomic literature? The controversial issue of price confidentiality

Pierluigi Russo

31-35
- PDF
- ePub
- html

Original Research Articles

Budget Impact analysis of a new system of care in Parkinson’s disease patients

Chiara Bini, Francesco Saverio Mennini, Andrea Marcellusi, Martina Paoletti, Carlo Tomino

91-98
- PDF
- ePub
- html
Cost-benefit analysis of ALK diagnosis vs. non-diagnosis in patients with advanced non–small cell lung cancer in Spain

Margarita Majem, Rosa Álvarez, Ana Laura Ortega, Lucía Ruiz de Alda, Rocío Gordo, J Francisco García, Yoana Ivanova-Markova, Almudena González-Domínguez, Raquel Sánchez San Cristóbal, Federico Rojo

82-90
- PDF
- ePub
- html
The costs incurred by patients to get eligibility to PCSK9 treatment and one-year follow-up: the results of the PRIOR Study

Arianna Bertolani, Roberto Ravasio, Paola Raimondo, Claudio Jommi

73-81
- PDF
- ePub
- html
Analysis of the evolution of the price of oncology drugs after the loss of their patent and the marketing of generic medicines

José Manuel Martínez-Sesmero, Borja Smith, Julen Madurga

68-72
- PDF
- ePub
- html
Introduction of the telemonitoring device Turbo+ in the management of patients suffering from asthma in Italy: a budget impact analysis

Filippo Rumi, Michele Basile, Americo Cicchetti, Rosario Contiguglia, Antonella Pentassuglia, Alessandro Oliva, Gianenrico Senna, Marco Bonavia, Francesco Scarpelli, Marco Benvenuto

58-67
- PDF
- ePub
- html
Cost-utility analysis of ceftolozane/tazobactam vs meropenem in patients with hospital-acquired pneumonia (HABP) or ventilator-associated pneumonia (VABP)

Francesco Saverio Mennini, Martina Paoletti, Chiara Bini, Andrea Marcellusi, Marco Falcone, Massimo Andreoni

45-57
- PDF
- ePub
- html
Distribution methods of ostomy and incontinence aids in the Italian healthcare setting: an evaluation questionnaire and social burden of direct distribution

Filippo Rumi, Francesca Orsini, Vincenzo Falabella, Pier Raffaele Spena, Americo Cicchetti

36-44
- PDF
- ePub
- html
Budget Impact Analysis of afatinib for first-line treatment of Non-Small Cell Lung Cancer (NSCLC) patients with uncommon EGFR mutations

Giuseppe Pompilio, Alessandro Morabito, Diego L. Cortinovis, Davide Integlia

22-29
- PDF
- ePub
- html
A multicriteria decision analysis (MCDA) applied to three long-term prophylactic treatments for hereditary angioedema in Spain

Néboa Zozaya, Teresa Caballero, Teresa González-Quevedo, Pedro Gamboa Setien, M. Ángeles González, Ramón Jódar, José Luis Poveda-Andrés, Encarna Guillén-Navarro, Agustín Rivero Cuadrado, Álvaro Hidalgo-Vega

14-21
- PDF
- ePub
- html
Use of a maturity model for facilitating the introduction of CAR T-cell therapy—Results of the START CAR-T project

Stefania Bramanti, Matteo Carrabba, Alice Di Rocco, Elena Fabris, Luca Gastaldi, Paolo Locatelli, Maria Chiara Tisi

1-8
- PDF
- ePub
- html

Short Communication

Cost analysis of extended half-life recombinant factor IX products in the treatment of haemophilia B in Italy: an update

Andrea Aiello, Maria E. Mancuso, Serena Leone, Letizia Rossi, Lorenzo Cioni, Cristina Teruzzi

9-13
- PDF
- ePub
- html

Erratum

Erratum in: Cost per responder for upadacitinib vs abatacept in patients with moderate-to-severe Rheumatoid Arthritis in Italy

30
- PDF
- ePub
- html